Sutimlimab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric/humanized hybrid |
Target | complement component 1s |
Clinical data | |
Synonyms | BIVV009 |
ATC code |
|
Identifiers | |
CAS Number |
Sutimlimab (BIVV009) (INN[1]) is a monoclonal antibody that is being investigated for cold agglutinin disease.
This drug is being developed by Bioverativ. As of 2018, sutimlimab is undergoing Phase III trials.
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.